Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Category Primary study
ConferenceAnnual Meeting of the Austrian Society of Haematology and Medical Oncology
Year 2024
This article has no abstract
Epistemonikos ID: c99dd6f62cee3fa75f3b8c4b28c929dea681b1d6
First added on: Nov 21, 2025